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Abstract
Background: Presently, preterm birth is globally the leading cause of neonatal mortality. Prompt community based
identification of women at high risk for preterm births (HRPB) can either help to avert preterm births or avail effective
interventions to reduce neonatal mortality due to preterm births. We evaluated the performance of a package to train
community workers to detect the presence of signs or symptoms of HRPB.
Methods: Pregnant women enrolled in the intervention arm of a cluster randomized trial of Antenatal Corticosteroids
(ACT Trial) conducted at Nagpur, India were informed about 4 directly observable signs and symptoms of preterm
labor. Community health workers actively monitored these women from 24 to 36 weeks of gestation for these signs or
symptoms. If they were present (HRPB positive) the identified women were brought to government health facilities for
assessment and management. HRPB positive could also be determined by the provider if the woman presented
directly to the facility. Risk stratification was based on the number of signs or symptoms present. The outcome of
preterm birth was based on the clinical assessment of gestational age < 37 weeks at delivery or a birth weight of <2000 g.
Results: Between July 1, 2012 and 30 November, 2013, 686 of 7050 (9.7%) pregnant women studied, delivered preterm.
732 (10.4%) women were HRPB positive, of whom 333 (45.5%) delivered preterm. Of the remaining 6318(89.6%) HRPB
negative women 353 (5.6%) delivered preterm. The likelihood ratio (LR) of a preterm birth in the HRPB positives was 8.14
(95% confidence interval 7.16–9.26). The LR of a preterm birth increased in women who had more signs or symptoms of
HRBP (p < 0.00001). More signs or symptoms of HRPB were also associated with a shorter time to delivery, lower birth
weight and higher rates of stillbirths, neonatal deaths and postnatal complications. Addition of risk stratification improved
the prediction of preterm delivery (Integrated Discrimination Improvement 17% (95% CI 15–19%)).
Conclusions: The package for detection of signs and symptoms of HRPB is feasible, promising and likely to
improve management of preterm labor.
Trial registration: NCT01073475 on February 21, 2010 and NCT01084096 on March 9, 2010.
Keywords: Preterm birth, Risk stratification, Diagnostic accuracy, Community workers

Background
The World Health Organization estimates that every
year approximately 15 million babies are born prematurely and 1 million of these babies die despite available
interventions that could save 75% of them [1]. Globally,
preterm birth is increasing and is now the leading cause
of death in neonates and children under age 5 [2]. In
addition to mortality, the burden of preterm birth results
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from significant lifetime disability in survivors, accounting for 3.1% of all Disability Adjusted Life Years (DALYs)
[3, 4]. This burden of disease is primarily due to breathing problems, feeding difficulties and neurological problems, with effects reaching into adulthood [5].
The vast majority (85%) of preterm births occur in low
and lower middle income countries in Asia and Africa
[5]. India has the highest number of preterm births in
the world accounting for 23.6% of the global burden
with approximately 1 in 8 babies being preterm [1]. It is
difficult to recognize preterm labor in under-equipped,
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lower level facilities since access to ultrasound assessments and measurement of biochemical markers such as
fetal fibronectin is limited in these settings [6]. Failure to
identify women at high risk for preterm birth in rural
communities, delays access and utilization of interventions that may prevent preterm deliveries.
Currently the standard of care for pregnant women at
high risk of preterm birth (HRPB) is administration of
antenatal corticosteroids at least 48 h before delivery [7,
8]. In a systematic review based on 18 trials in resource
rich countries, antenatal corticosteroids resulted in a 34%
reduction in the incidence of RDS, a 46% reduction in intraventricular hemorrhage and a 31% reduction in neonatal mortality [9]. In resource limited settings, antenatal
corticosteroids are available only at tertiary health care facilities that can administer antenatal corticosteroids and
offer other specialized perinatal interventions that improve preterm outcomes and is rarely accessible to pregnant women in rural communities. Moreover, the
common causes of preterm births include anemia, maternal infections, antepartum hemorrhage and pregnancy induced hypertension [2]. Thus early identification of HRPB
women can also have additional benefits in terms of recognition of these other obstetric conditions associated
with preterm births. Therefore, there is an urgent need to
identify pregnant women at HRPB well before delivery.
We recently participated in a multi-site cluster randomized trial conducted by the Global Network for
Women and Children’s Health Research [10]. This trial
(the ACT Trial) evaluated a multifaceted intervention
for detection of women at HRPB so that they could receive antenatal corticosteroids with a goal of improving
neonatal outcomes. Accuracy of how well this intervention performed to predict preterm births was evaluated
using the data from the ACT trial. Furthermore we evaluated whether risk stratification based on number of
symptoms present, improved prediction of delivering a
preterm baby.

Methods
Study design, setting, and ethics statement

This study is a secondary data analysis using data from
the intervention arm of the ACT Trial [10, 11] and Maternal and Newborn Health (MNH) Registry [12] supported by the Eunice Kennedy Shriver National Institute
of Child Health and Human Development NICHD’s Global Network for Women’s and Health Research. For this
study, we used the data collected at the Nagpur, India
site of these multicenter studies.
For the MNH Registry, a prospective cohort of pregnant women was recruited as early as possible during
pregnancy and followed through day 42 (up to a maximum of 60 days) post-partum to obtain details about
the pregnancy, labor, delivery and the health of the
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mother and infant. In Nagpur, pregnant women were recruited consecutively from the rural communities in the
catchment areas of 20 Primary Health Centers (PHCs)
or clusters in 4 districts – Nagpur, Bhandara, Wardha
and Chandrapur. In the ACT trial, ten of the 20 PHCs
were randomized to the multifaceted ACT intervention
arm between June 11, 2012 and December 11, 2013.
Study variables for the ACT trial were collected in the
MNH Registry, supplemented by additional data collection in the ACT intervention clusters. Most babies
(99.02%) were born in health facilities as a result of
Janani Suraksha Yojana (JSY) that provides financial assistance for woman to promote institutional deliveries
and to ASHAs (Accredited Social Health Activist) who
bring the expectant mother to institutions for delivery.
This scheme has substantially increased rates of deliveries at facilities in India [13].
Participants

We included women enrolled in the MNH Registry before week 24 of pregnancy (Fig. 1) and excluded those
enrolled in the ACT trial control clusters because there
was no detection of HRPB in the control clusters. Additional exclusion criteria for this secondary data analysis
included: i) miscarriage or medical termination of pregnancy; ii) no information about gestational age prior to
delivery; and iii) missing birth weight.
Definition and risk stratification of HRPB

Women were classified as HRPB positive if they had one
or more of the 4 following signs or symptoms of preterm
labor during the risk period of week 24–36 of gestation: (1)
intermittent abdominal pain or pain associated with bloodstained mucus discharge, watery vaginal discharge or a
sudden gush of water (Signs of preterm labor); (2) watery
vaginal discharge or a sudden gush of water with or without cramping (Premature rupture of membranes); (3) vaginal bleeding with or without cramping (hemorrhage), and
(4) severe headache (hypertension) [10]. Risk of preterm
birth was further stratified by the number of signs or symptoms present ranging from 0, 1, 2 or 3 or more. The HRPB
definition did not include a history of previous preterm
birth, a well-recognized predictor of preterm birth, [2, 14]
because of the difficulty in obtaining a reliable history of
previous spontaneous preterm birth in rural settings [10].
Intervention package to determine HRPB

The multifaceted HRPB package consisted of four components – i) training at multiple levels regarding signs or
symptoms of preterm labor, ii) monitoring in the community between week 24 and 36 of gestation by community
health worker or ASHA worker, iii) determination of
whether the pregnant woman was positive using the HRPB
signs or symptoms by ASHA worker in the community,
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Women Enrolled in MNH registry
N = 15120
Women from Control Clusters
N=7692

Women from ACT intervention Clusters
N = 7424
Miscarriage or MTP
N=298
LMP, EDD, Birth weight or gestation at
birth missing
N=70
Women whose GA at assessment was out
of eligible range for HRPB (<24 or >36
weeks)
N=6
Women eligible for HRPB Assessment
N = 7050
HRPB intervention for identification was applied by
trained providers

HRPB Positive
N=732

HRPB Negative
N=6318 (89.6

Fig. 1 Flow diagram of study participants

and, iv) confirmation of the HRPB signs or symptoms
by a health care provider (HCP) at the Primary Health
Center (PHC), sub-center (SC) or other referral facility
to determine eligibility for administration of ACT in a
woman who is brought to the center by an ASHA or
who is self referred.
Multi-level training for signs or symptoms to detect HRPB

Awareness regarding the 4 signs or symptoms of preterm labor during the risk period (week 24–36 of gestation) was created in the community and in households
with pregnant women. The pregnant women also received pamphlets containing these details as reminders.
The ASHA workers who live in the community and are
responsible for about 10 pregnant women were trained
by study obstetricians to ask and recognize the signs or
symptoms and record positive responses on the women’s
tracking card (the Nagpur based study staff informed the
ASHA workers when the risk period started and ended
i.e. week 24–36 week of gestation). Training started with
a pre-training questionnaire to assess baseline knowledge about preterm birth, its consequences and how to
identify women who might be at HRPB. It was followed
by audio-visual presentations supplemented by posters,
pamphlets and manuals translated into the local language (Marathi), role-playing with qualified obstetricians, and learning how to use an obstetric disc and a

color coded tape to assess fundal height and estimate
gestational age (see [10] for details of the use of tape).
They were also trained to track the pregnant women
during the risk period by conducting weekly home visits,
to ask about signs or symptoms of HRPB and to record
positive responses on the woman’s tracking card and to
record. The HCPs in 10 PHCs and their attached SCs
(first level facilities) and 15 referral facilities were trained
by study obstetricians to recognize the signs or symptoms of HRPB in a similar way to the ASHA workers, as
described above. They were retrained every 6 months.

Monitoring, determination and confirmation of HRPB

The ASHA tracked each pregnant woman by conducting
weekly home visits during the risk period and recorded
positive HRPB signs or symptoms on tracking cards.
They brought women who were positive for HRPB to a
health facility which could be the SC or PHC or a referral facility. The HCP would confirm HRPB positivity and
administer ACT. Women could also directly reach the
health facilities, if they suspected that they felt that they
were at high risk for preterm birth. The HCP were the
auxiliary nurse midwives (ANMs) at SCs, the medical officers at the PHC, and the nurses, residents and obstetricians at the referral facilities. Each pregnant woman
could be evaluated multiple times if she reported signs
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or symptoms at different times, but she could be HRPB
positive only once.
Primary outcome - preterm birth

The primary outcome of interest was whether the pregnant women delivered a preterm or term baby based on
the reported gestational age at birth and birth weight from
the MNH registry. The medical officers at the place of delivery routinely use a combination of the following criteria
to report gestational age at birth: 1) date of last menstrual
period if menses are regular, 2) first trimester ultrasound
if available, 3) birth weight 4) clinical evaluation of the
neonate. Based on these reports, a baby was considered
preterm if the reported gestational age was <37 weeks.
Birth weight < 2000 g (5th percentile of birth weight) was
also considered a preterm birth. The GN study used birthweight rather than gestational age for the primary analysis
subgroup because many women in the registry had missing or uncertain gestational age, ultrasound was often unavailable, and the intervention was designed to improve
estimation of gestational age, which could potentially bias
gestational age-based analyses [10].
Data source and assessment

Trained study staff collected data for the MNH Registry
at three time points. The first time point was on enrolment (before the 20th week of gestation whenever possible), during which information on the date of last
menstrual period, estimated delivery date, age, education, parity, and status of their last child is collected.
The second time point was within 7 days of delivery, information is collected on prenatal care, birth preparedness, complications occurring during pregnancy, details
of labor and delivery, including place, mode of delivery,
provider, actual birth weight obtained at the time of
birth, status of the mother and newborn (including term
or preterm as noted by the facility physician or specialist) following delivery, referrals, and treatment provided
to the mother and newborn at referral facilities. The
third time was 42 (up to a maximum of 60) days after
birth. Separately trained ACT trial study staff tracked
women who were HRPB positive from place of identification to the facility where they received the antenatal
corticosteroids and delivered.
Statistical analysis

Performance of the package of intervention to identify
HRPB women was assessed using likelihood ratios (LR)
for each risk category. Likelihood ratio was defined as
the ratio of post-test probability and prevalence of preterm birth for each risk category. We used methods described by Centor [15] to estimate the LRs and their
95% confidence intervals (CI). To estimate the independent contribution of HRPB risk stratification for the
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identification of preterm births, we used multivariable
generalized estimating equations (GEE) to account for
inter-cluster variation and the following covariates:
mother’s age, mother’s education, parity, and presence of
anemia. Dose-response was assessed using the
Cochrane-Armitage test for linear trend and categoryspecific probability of a preterm birth. Improvement in
the prediction of a preterm birth based on the package
of intervention was evaluated using the integrated discrimination improvement (IDI) and the net reclassification index (NRI) [16]. We used the IDI and NRI
packages (http://personalpages.manchester.ac.uk/staff/
mark.lunt) to determine the IDI and NRI values (continuous version without using cut-offs), respectively.
These programs directly compare the discrimination and
reclassification ability of a new predictor over and beyond the predictors included in the baseline model.
Finally, we explored whether there were associations between increasing number of signs or symptoms of HRPB
and time to delivery, birth weight and neonatal outcomes
using the Cochrane-Armitage test for linear trend. Data
were analyzed using Stata 13.1 package (Stata Corp, College Station, Texas, USA). Statistical significance was
tested with two-tailed tests and a type I error rate of 0.05.

Results
Of the women enrolled in the ACT trial between July 1,
2012 and 30 November, 2013, a total of 7050 pregnant
women were included in the final analysis of this study
(Fig. 1). Table 1 shows the characteristics of the women.
The majority were between age 20 and 25 years, had secondary or higher educational background, and were
anemic. Forty-five percent were nulliparous. In the parous
women, 96% women had a history of previous live birth.
Presence of signs or symptoms of HRPB was first made by
the ASHA workers for 73% of the women diagnosed as
HRPB, with an additional 22% being identified at a PHC
and the remaining 5% identified at a referral hospital.
Prevalence of preterm births

A total of 686 babies were considered preterm (prevalence 9.7% (95% CI 9.0–10.4%). Of these, 558 (81%) were
identified based on clinical assessment at birth and 128
(19%) based on a birth weight of <2000 g. The distribution of the preterm births were 11% between 24 and
27 weeks of gestation, 22% between 28 and 31 weeks of
gestation and 67% between 32 and 36 weeks of gestation.
Of the 6364 term births 721(11%), were small for gestational age with weight between 2000 g and 2500 g.
Performance of the HRPB package to detect preterm
births

Of the 7050 women included in this study, 732 (10.4%)
were HRPB positive. Of these 732 women, 333 delivered
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Table 1 Characteristics of the Study Population (N = 7050)
Characteristic

Preterm

Term

Total

N = 732 (100) N = 6318 (100) 7050 (100)
Mother’s Age
<20

17 (2.32)

99 (1.57)

116 (1.65)

20–25

570 (77.87)

4833 (76.5)

5403 (76.64)

>25

145 (19.81)

1386 (21.94)

1531 (21.72)

None-Primary

172 (23.5)

1361 (21.54)

1533 (21.74)

Secondary

456 (62.3)

3792 (60.02)

4248 (60.26)

University

104 (14.21)

1152 (18.23)

1256 (17.82)

Nulliparous

366 (50)

2828 (44.76)

3194 (45.3)

1–2

344 (46.99)

3325 (52.63)

3669 (52.04)

>2

22 (3.01)

165 (2.61)

187 (2.65)

Mother’s Educationa

Parity

Previous birth live (for parity ≥1)
Yes

343 (93.7)

3354 (96.1)

3697 (95.9)

No

23 (6.28)

136 (3.9)

159 (4.1)

506 (8.01)

542 (7.69)

Maternal Anemia (Hemoglobin g%)a
Not anemic (≥11)

36 (4.92)

Mild (10–11)

262 (35.79)

2636 (41.72)

2898 (41.11)

Moderate/ Severe (<10) 434 (59.29)

3143 (49.75)

3577 (50.7)

Hypertension
Yes

132(18.03)

0(0.00)

132(1.87)

No

600(81.97)

6318(100.00)

6918(98.13)

a

missing information on maternal education (n = 13 (0.2%) and anemia
(n = 33 (0.5%))

a preterm baby (positive predictive value 48.5%, 95% CI
44.7% – 52.4%). The false negative rate was 5.6% and
false positive rate was 54.5%. The frequency and proportion of HRPB symptoms, and the test characteristics for
each symptom are described in Table 2. The likelihood
ratio associated with being HRPB positive was 8.1 (95%
CI 7.2–9.3). As shown in Table 3 the LR of a preterm
birth increases with increasing number of signs or symptoms, specifically from a probability of preterm birth in
women with no signs or symptoms of 6% to 68% in
those who had 3 or more signs or symptoms. Furthermore, the mean birth weight consistently decreased with
increasing number of symptoms from a mean of 2704 g
(+/− 402) for no signs or symptoms to 2429 g (+/− 549)

for 1 sign or symptom, 2308 g (+/− 557) for 2 signs or
symptoms and 2187 g (+/− 616) for 3 or more signs or
symptoms. The Cochrane-Armitage test for linear trend
was highly significant (p < 0.0001). In the multivariable
GEE analysis, we found that independent of other clinical covariates, the number of high risk symptoms was a
statistically significant predictor of preterm births. The
odds ratio for preterm birth was 10.3, 19.4 and 37.7
when 1, 2 or 3 or more HRPB signs or symptoms respectively were present.
Risk stratification and time to delivery and neonatal
outcomes

Figure 2 shows that the likelihood of a delivery over time
indicating that more signs or symptoms of HRPB was
associated with shorter time to delivery and fewer signs
or symptoms were associated with longer time to delivery. We found that over 40% of the pregnancies continued for four or more weeks from the time of
identification but the probability was only 11% when
there were 3 symptoms as compared to 53% when there
was only 1 symptom. We also investigated the association of risk stratification with neonatal outcomes. The
7050 women delivered 97 (1.4%) stillbirths, 207 (2.9%)
neonates died and 471 (6.7%) babies had at least one
postnatal complication (feeding problems, congenital
anomalies, breathing problems, high fever, hypothermia
and convulsions singly or in various combinations).
Table 4 shows the risk of adverse neonatal outcomes
using generalized estimating equations that accounted
for inter-cluster variations. The risk of stillbirths, postnatal death and postnatal complications was significantly
associated with the number of signs or symptoms of
HRPB identified by the community health workers and
the risk of all neonatal outcomes increased significantly
with increased number of signs or symptoms.
Improvement in prediction of a preterm birth using risk
stratification

Lastly, we investigated whether the addition of being
HRPB positive to a base model that included maternal
age and education, parity and anemia improved the prediction of preterm birth. These covariates were chosen
on the basis of their significant statistical association
with the outcome of preterm labor (Table 1). The IDI
value for the addition of being HRPB positive was

Table 2 Frequency and proportion of HRPB symptoms, and the test characteristics of each symptom
Symptom

N (% out of 7050)

Sensitivity

Specificity

Positive Predictive Value

Negative Predictive Value

Signs of Preterm Labor

540 (7.66)

49.3%

93.5%

38.8%

95.7%

Premature rupture of membrane

251 (3.56)

52.6%

91.9%

19.2%

98.1%

Hemorrhage

71 (1.01)

64.8%

90.8%

6.7%

99.6%

Hypertension

132 (1.87)

37.9%

90.8%

7.3%

98.7%
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Table 3 Performance of Risk-Stratification as a Predictor of Preterm Birth
Number of HRPB
Signs or symptoms

Outcome – Reference Standard (N)
Preterm

Term

0

353

1
2

Probability of Delivering
Preterm

Likelihood Ratio (95%
Confidence Interval)

Odds Ratio from GEE Model
(95% Confidence Interval) a

5965

0.06

0.55 (0.50–0.60)

Reference

173

273

0.39

5.89 (4.44–7.81)

10.3 (8.14–13.0)

139

116

0.55

11.05 (7.51–16.27)

19.4 (14.6–25.8)

0.68

19.51 (0.84–454.0)

37.7 (17.4–81.9)

3 or more

21

10

Total

686

6364

a

Results are based on multivariable logistic regression analyses that included the following covariates and was adjusted for inter-cluster differences using GEE:
mother’s age, education, parity and anemia
Cochran - Armitage test for linear trend: Χ2 (1 df) = 1215.81, p = 2.2 × 10−266

16.78% (95% CI 14.93–18.63%) and the NRI was 30.61%
(95% CI 25.31–35.91%), both of which are highly significant (p < 1.0 × 10−22). These indexes thus showed that
being HRPB positive clearly improved the prediction of
women delivering a preterm baby over and above a baseline risk.

Discussion
In this secondary analysis of pregnant women in rural
communities near Nagpur, Central India who received a
package of interventions to detect those at HRPB, we
found that identification of any of the 4 specific signs or
symptoms of preterm labor was an independent predictor of a subsequent preterm birth. The LR+ were >5
and ranged from 5.9 for presence of 1 symptom to 19.5
for presence of 3 or more symptoms. In addition, the
number of signs or symptoms of HRPB directly translated into an increasing risk of preterm birth, a decreasing birth weight, higher likelihood of early delivery and
higher risk of adverse neonatal outcomes. The package
was easy to use and implement in a rural setting and improved the risk stratification of the pregnant women at
HRPB. Honest et al. identified a combination of tests
predicting preterm births. Only a few tests had LR+ > 5.

In asymptomatic women these were ultrasonographic
cervical length measurement and cervicovaginal prolactin and fetal fibronectin screening for predicting spontaneous preterm birth before 34 weeks. In symptomatic
women with threatened preterm labour, tests with LR
+ > 5 were absence of fetal breathing movements, cervical length and funnelling, amniotic fluid interleukin-6
(IL-6), serum CRP for predicting birth within 2–7 days
of testing, and matrix metalloprotease-9, amniotic fluid
IL-6, cervicovaginal fetal fibronectin and cervicovaginal
human chorionic gonadotrophin (hCG) for predicting
birth before 34 or 37 weeks [17]. These investigation are
unavailable and not feasible in low resource settings.
The overall prevalence of preterm birth in this community was 10% which is lower than the reported prevalence of 13% preterm births in India [1] Our lower
prevalence of preterm birth may be due to recent improvements in community obstetric care, continuum of
care and facility based deliveries at our study site [8, 10].
All babies <5th percentile were considered preterm
due to lack of reliable ascertainment of GA in rural
population. Only 19% of the preterm births were identified based on birth weight. Low Birth Weight (LBW)
was used as a proxy for preterm birth because in Global

Fig. 2 Time to delivery in women at HRPB by number of signs or symptoms
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Table 4 Neonatal Outcomes by Number of Signs or Symptoms of HRPB
Outcome

a

Number of symptoms

Ptrend

1

2

3 or more

Stillbirths

2.64 (1.45–4.80)

3.96 (2.07–7.57)

6.06 (1.42–25.8)

χ2 = 32.73, P < 0.001

Postnatal deaths

3.21 (2.17–4.75)

2.25 (1.27–3.98)

4.22 (1.28–14.1)

χ2 = 32.93, P < 0.001

Postnatal complications

2.56 (1.80–3.63)

2.95 (1.95–4.45)

5.11 (2.16–12.1)

χ2 = 87.14, P < 0.001

a

Cochrane-Armitage test for linear trend

Network sites approximately 15% of the women who delivered at health centers or homes did not know their
LMP dates, and 40% of the deliveries occurred at the
community level, where ultrasound is not available.
We found that over 40% of the pregnancies continued for
four or more weeks from the time of symptom identification. However, when we investigated the distribution of the
time interval between risk stratification and delivery based
on the gestational age at which women were enrolled, we
observed that those enrolled early during pregnancy (e.g.
24–28 weeks) were more likely to continue the pregnancy
for ≥4 weeks as compared to women who were enrolled
later on (Fig. 2). Considering that most of the women with
only one risk symptom were able to continue pregnancy
for ≥4 weeks beyond risk stratification, it is conceivable that
the package of interventions may lend itself to a lead-time
bias [18]. It is possible, for example, that the package of
intervention may be more accurate in risk stratifying
women closer to term than in earlier during pregnancy.
Consequently, the optimum time point in pregnancy at
which the package of intervention will be most beneficial in
community settings is currently unknown. More studies
are required to address this important operational issue.
Our study has some limitations that were imposed by
ACT trial protocol. First, the inclusion and exclusion criteria for the trial may make our study population different
from many rural populations. Secondly, ultrasound corroboration of gestational age was rarely available. Third
our reference standard to define preterm birth based on
clinical evaluation and birth weight may have resulted in
misclassification of preterm birth. The magnitude and direction of the influence of misclassification on the performance of the package of intervention is not known. We did
try to address this by running sensitivity analyses to model
the influence of errors in reference standard on the estimates of likelihood ratios of being HRPB positive [19].
Figure 1 shows that even if the reference standard were to
inflate the prevalence of preterm birth by 10%, the estimated likelihood ratio for being HRPB positive would fall
from 8.1 (as reported in this study) to 7.6 – a negligible
decrease. Fourth, this was a symptom based intervention
to identify women at HRPB. It did not include clinical history such as previous preterm birth which may improve
the predictability of a preterm birth. Fifth, as discussed
above the package of intervention may be more accurate

in risk stratifying women closer to term than in earlier
during pregnancy. Sixth, if a woman at HRPB did not deliver within a short time of onset of symptoms, there was
no way to know whether the baby was actually premature
at the time of onset of symptoms, and perhaps reduced
the predictability of the HRPB intervention package. Finally, we have not studied the potential cost-effectiveness
analysis of the intervention package of intervention. If this
approach is found to be successful in other populations,
costs of training community health workers, costs of false
positive identification, etc. would need to be considered.

Conclusions
Currently in the rural areas of developing countries
there are no reliable methods to detect at risk mothers
for preterm deliveries. To our knowledge, this is the
first, large community based study that has evaluated
from a pragmatic standpoint a easy to use package of interventions to identify and risk stratify women at HRPB.
The HRPB package of interventions was found to be
useful where the community health workers who are the
first point of contact for most rural mothers provide a
strong link between communities and the health system.
This intervention could help to facilitate the administration of antenatal corticosteroids, but could be adapted to
other interventions to improve outcomes in preterm babies. Further studies are needed to refine this tool and
investigate its validity and acceptability in other populations with varying prevalence of preterm births and, different health care infrastructures. Furthermore the cost
effectiveness in reducing the burden of mortality due to
prematurity needs to be determined before it is adopted
for use in the public health settings.
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